[go: up one dir, main page]

AR132456A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR132456A1
AR132456A1 ARP240100975A ARP240100975A AR132456A1 AR 132456 A1 AR132456 A1 AR 132456A1 AR P240100975 A ARP240100975 A AR P240100975A AR P240100975 A ARP240100975 A AR P240100975A AR 132456 A1 AR132456 A1 AR 132456A1
Authority
AR
Argentina
Prior art keywords
novel compounds
compounds
novel
methods
general formula
Prior art date
Application number
ARP240100975A
Other languages
English (en)
Inventor
David Bon
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Anglique Patiny-Adam
Christian Schnider
Jonathan Martin Shannon
Sandra Steiner
Andreas Michael Tosstorff
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132456A1 publication Critical patent/AR132456A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula genera (1) en donde R¹, R², R⁹, A¹, Rˣ y Rʸ son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
ARP240100975A 2023-04-19 2024-04-18 Compuestos novedosos AR132456A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23168774 2023-04-19
EP23207285 2023-11-01

Publications (1)

Publication Number Publication Date
AR132456A1 true AR132456A1 (es) 2025-07-02

Family

ID=90720444

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100975A AR132456A1 (es) 2023-04-19 2024-04-18 Compuestos novedosos

Country Status (12)

Country Link
KR (1) KR20250174617A (es)
CN (1) CN120958000A (es)
AR (1) AR132456A1 (es)
AU (1) AU2024258000A1 (es)
CL (1) CL2025003121A1 (es)
CO (1) CO2025013412A2 (es)
CR (1) CR20250409A (es)
IL (1) IL323743A (es)
MX (1) MX2025011842A (es)
PE (1) PE20252682A1 (es)
TW (1) TW202448447A (es)
WO (1) WO2024218100A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067343A1 (zh) * 2023-09-27 2025-04-03 纽欧申医药(上海)有限公司 并环化合物及其应用
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019083A (ko) * 2021-06-04 2024-02-14 에프. 호프만-라 로슈 아게 트리아진 유도체 및 암 치료에서 이의 용도
WO2023066825A1 (en) 2021-10-19 2023-04-27 F. Hoffmann-La Roche Ag Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors

Also Published As

Publication number Publication date
KR20250174617A (ko) 2025-12-12
CR20250409A (es) 2025-10-30
IL323743A (en) 2025-11-01
CO2025013412A2 (es) 2025-10-09
CL2025003121A1 (es) 2025-11-14
AU2024258000A1 (en) 2025-08-14
CN120958000A (zh) 2025-11-14
MX2025011842A (es) 2025-11-03
TW202448447A (zh) 2024-12-16
PE20252682A1 (es) 2025-11-24
WO2024218100A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
CL2023003312A1 (es) Inhibidores de nlrp3
AR131282A1 (es) Compuestos novedosos
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
AR131006A1 (es) Compuestos novedosos
AR132456A1 (es) Compuestos novedosos
CL2020001871A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco.
CO2023004195A2 (es) Compuestos heterocíclicos
CO2023016212A2 (es) Derivados de triazina y su uso en el tratamiento del cáncer
CO2023014721A2 (es) Compuestos heterocíclicos
AR130984A1 (es) Compuestos novedosos
UY39526A (es) Inhibidores de kras g12d
CL2025001654A1 (es) Compuestos novedosos como moduladores de la inhibición de nlrp3
MX2024012029A (es) Moduladores del transductor de señal y activador de la transcripción y usos de los mismos
AR132377A1 (es) Compuestos novedosos
CL2022000802A1 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CO2025003256A2 (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
CL2025000126A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CL2025000125A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CL2025002125A1 (es) Compuestos novedosos
ECSP23091202A (es) Moduladores de trex1
CL2023001565A1 (es) Inhibidores de enzimas
AR133076A1 (es) Compuestos novedosos